Intellectual Property

Pharma Two B’s investigational products are based on previously approved drugs, however, the novel modifications, combinations and formulations used in the development, lead to innovative new products with unexpected improvements that provide basis for strong intellectual property.

P2B001, a novel low dose investigational product for the treatment of Parkinson’s disease, was granted a patent in 15 countries, with both Pharmaceutical Matter and Method of treatment patents granted in the US.

Additional patents include unique release profiles and other low dose combinations.